Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Pharma Pipeline Transparency Makes It Hard To Hide Negative Clinical Trials
Forbes
Monday, February 25, 2013 - 9:45am
tags:
clinical trials
Strides Arcolab looks to sell stake worth Rs 4,885 cr
Business Standard, India
Sunday, February 24, 2013 - 2:53pm
tags:
Strides Arcolab
How Valeant became Canada's hottest stock
Globe and Mail, Canada
Sunday, February 24, 2013 - 2:51pm
tags:
Valeant Pharmaceuticals
Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
PharmaLive
Sunday, February 24, 2013 - 2:40pm
tags:
Immune Pharmaceuticals, bertilimumab, ulcerative colitis
Why Buyers Sent Infinity 550% Higher In The Last Year
Proactive Investors
Sunday, February 24, 2013 - 2:38pm
tags:
Infinity Pharmaceuticals
Dendreon Earnings: An Early Look
Motley Fool
Sunday, February 24, 2013 - 2:36pm
tags:
Dendreon
3 Humongous Health-Care Stocks This Week
Motley Fool
Sunday, February 24, 2013 - 2:36pm
tags:
Infinity Pharmaceuticals, Celldex, Questcor Pharmaceuticals
China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment
Seeking Alpha
Sunday, February 24, 2013 - 2:34pm
tags:
Golong Medicine, Reckitt Benckiser, M&A, Sihuan Pharma, Regeneron, Luye Pharma Group, Bayer, Double-Crane Pharma
SP-333 Targets Root Cause Of Irritable Bowel Syndrome
Motley Fool
Sunday, February 24, 2013 - 2:31pm
tags:
SP-333, irritable bowel syndrome, Synergy Pharmaceuticals
5 Can't-Miss Health-Care Events This Week
Motley Fool
Sunday, February 24, 2013 - 2:29pm
tags:
Onyx, Bayer, Zogenix, Ariad, Questcor, Medivation
A Global Leader in Animal Health - Spinoff Opportunity?
Motley Fool
Sunday, February 24, 2013 - 2:27pm
tags:
Zoetis
Johnson & Johnson's Pioneering Zytiga And Its Competitors
Seeking Alpha
Sunday, February 24, 2013 - 2:24pm
tags:
Zytiga. ARN-509, Xtandi, prostate cancer, Medivation, JNJ, Astellas, Aragon, Tokai
Is AbbVie Wasting Your Money?
Motley Fool
Sunday, February 24, 2013 - 2:23pm
tags:
AbbVie
J&J Hip Designer Says He Gave Complaints to Marketers
Bloomberg
Sunday, February 24, 2013 - 2:22pm
tags:
JNJ, hip replacements, devices, recalls, hip recall
Affymax, Takeda recall anaemia drug Omontys after deaths
Reuters
Sunday, February 24, 2013 - 2:20pm
tags:
Takeda, recalls, Omontys, Affymax
This Week in Biotech
Motley Fool
Sunday, February 24, 2013 - 2:20pm
tags:
Roche, Immunogen, Repros Therapeutics, Chelsea Therapeutics, Gilead Sciences, Vivus
BGI-Shenzhen Extends Tender Offer For Complete Genomics, inc.
Yahoo/PR Newswire
Sunday, February 24, 2013 - 2:18pm
tags:
BGI-Shenzhen, Complete Genomics, M&A
Vivus, Inc.: Second Rejection And Upcoming Earnings, Patience Required For Investors
Seeking Alpha
Friday, February 22, 2013 - 11:37am
tags:
Vivus, earnings, Qsymia
EMA recommends extended indications for Glaxo's Cervarix
Yahoo/Fly on the Wall
Friday, February 22, 2013 - 11:12am
tags:
GSK, Cervarix, Europe, HPV
InterMune Earnings: Here’s Why Shares are Up Now
Wall St. Cheat Sheet
Friday, February 22, 2013 - 11:10am
tags:
earnings, InterMune

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.